查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1692312

頭頸癌藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、配銷通路、地區和競爭細分，2020-2030 年預測

Head and Neck Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球頭頸癌藥物市場價值為 19.5 億美元，預計到 2030 年將達到 27.5 億美元，預測期內的年複合成長率(CAGR) 為 6.11%。癌症仍然是全球面臨的重大健康挑戰，影響著全球數百萬人的生活。在眾多癌症類型中，頭頸癌特別複雜且難以治療。其包括在口腔、咽、喉、鼻竇和鼻腔中發展的腫瘤，會嚴重影響患者的生活品質，需要專門的治療。全球頭頸癌藥物市場透過提供創新的治療方案在解決這個醫療問題中發揮關鍵作用。這種癌症類型會影響上呼吸道和消化道的幾個部分，包括口腔、喉嚨、聲帶、鼻竇和唾液腺。已知的風險因素包括吸煙和飲酒、人類乳突病毒 (HPV) 感染以及接觸各種化學物質和刺激物。

市場概況
預測期 2026-2030
2024 年市場規模 19.5 億美元
2030 年市場規模 27.5 億美元
2025-2030 年複合年成長率 6.11％
成長最快的領域 免疫療法
最大的市場 北美洲

頭頸癌藥物市場由持續的研究和開發努力推動，旨在改善治療效果和提高患者的生活品質。推動市場成長的關鍵因素是頭頸癌發生率的上升，尤其是由於 HPV 感染導致的年輕族群。早期發現和有效治療對於提高存活率至關重要。精準醫療、免疫治療等醫療技術的進步，推動了標靶治療和個人化治療方案的發展，療效更佳，副作用更少。手術、化療和放射療法等傳統治療方法正在被免疫療法（例如檢查點抑制劑）和標靶療法（例如 EGFR 抑制劑）等新療法所補充。

主要市場促進因素：

頭頸癌發生率不斷上升

主要市場挑戰：

高發病率

主要市場趨勢：

技術進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：COVID-19 對全球頭頸癌藥物市場的影響

第5章：全球頭頸癌藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別（化療​​、免疫療法、標靶治療）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太地區頭頸癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章：歐洲頭頸癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美頭頸癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 9 章：南美洲頭頸癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲頭頸癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國頭頸癌藥物市場展望
      • 市場規模和預測
        • 按價值
      • 市場佔有率和預測
        • 按藥物類別
        • 按配銷通路

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球頭頸癌藥物市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Astrazeneca Plc.
  • Fresenius Medical Care AG & CO. KGAA
  • F.Hoffmann-la Roche Ltd.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 19779

The global Head and Neck Cancer Drugs Market was valued at USD 1.95 billion in 2024 and is projected to reach USD 2.75 billion by 2030, with a compound annual growth rate (CAGR) of 6.11% during the forecast period. Cancer remains a significant global health challenge, affecting millions of lives worldwide. Among the various cancer types, head and neck cancer is particularly complex and difficult to treat. It includes tumors that develop in the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, and can severely impact patients' quality of life, requiring specialized treatments. The global head and neck cancer drugs market plays a critical role in addressing this medical issue by providing innovative therapeutic solutions. This cancer type affects several components of the upper respiratory and digestive tracts, including the mouth, throat, voice box, sinuses, and salivary glands. Known risk factors include tobacco and alcohol use, human papillomavirus (HPV) infection, and exposure to various chemicals and irritants.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.95 Billion
Market Size 2030USD 2.75 Billion
CAGR 2025-20306.11%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

The head and neck cancer drugs market is driven by ongoing research and development efforts aimed at improving treatment outcomes and enhancing patient quality of life. A key factor contributing to market growth is the rising incidence of head and neck cancer, particularly among younger individuals due to HPV infections. Early detection and effective treatment are essential for improving survival rates. Advances in medical technologies, such as precision medicine and immunotherapy, have led to the development of targeted therapies and personalized treatment plans, which are more effective and have fewer side effects. Traditional treatments like surgery, chemotherapy, and radiation therapy are being supplemented by newer options, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies (e.g., EGFR inhibitors).

Key Market Drivers:

Increasing Incidence of Head and Neck Cancer

Head and neck cancer is a complex group of diseases that affect the oral cavity, throat, larynx, and nasal passages. This type of cancer significantly impacts patients' quality of life and has been steadily increasing in incidence worldwide. According to Global Cancer Statistics, head and neck cancer ranks as the third most common cancer globally, with 1.46 million new cases and 487,993 deaths, accounting for 7.6% of all cancer cases and 4.8% of cancer-related deaths globally. This growing burden, coupled with advancements in cancer treatments, is driving demand for innovative therapies. The market for head and neck cancer drugs is anticipated to experience significant growth as the healthcare sector prioritizes cancer care and patients increasingly seek effective treatment options. Risk factors for head and neck cancer include tobacco and alcohol use, HPV infection, and certain dietary habits. While smoking rates have declined, leading to a decrease in cancers related to the larynx, the rise in oropharyngeal cancers linked to HPV infection remains a concern.

Key Market Challenges:

High Incidence Rates

One of the primary challenges faced by the head and neck cancer drugs market is the high incidence of the disease. With cancers affecting the mouth, throat, and larynx among the most prevalent globally, the increased number of cases places significant pressure on healthcare systems. This rising incidence fuels demand for more effective treatments and medications.

Key Market Trends:

Technological Advancements

Technological advancements are playing a pivotal role in improving the diagnosis, treatment, and prognosis of head and neck cancer. These innovations are not only enhancing patient outcomes but also stimulating market growth. High-resolution imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) allow healthcare providers to detect and assess head and neck cancers with greater accuracy, facilitating early detection and timely intervention. Additionally, advances in genomics and proteomics have led to the identification of specific biomarkers associated with head and neck cancer. Biomarker-based tests enable early diagnosis and help develop personalized treatment plans tailored to individual patients. Telemedicine has also revolutionized healthcare delivery, allowing remote consultations and pathology reviews. This is especially important for head and neck cancer, as it enables specialists to provide expertise and collaborate in underserved or remote regions.

Key Market Players:

  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc.
  • Fresenius Medical Care AG & CO. KGAA
  • F. Hoffmann-La Roche Ltd.

Report Scope:

This report segments the Global Head and Neck Cancer Drugs Market into the following categories, in addition to providing insights into industry trends:

By Drug Class:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America: United States, Canada, Mexico
  • Europe: France, United Kingdom, Italy, Germany, Spain
  • Asia Pacific: China, India, Japan, Australia, South Korea
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section includes detailed analysis and profiles of major companies operating in the Head and Neck Cancer Drugs Market.

Available Customizations:

TechSci Research offers customization options for this market report, allowing adjustments based on specific company needs. Customization options include the profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Head and Neck Cancer Drugs Market

5. Global Head and Neck Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Chemotherapy, Immunotherapy, Targeted Therapy)
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Head and Neck Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Head and Neck Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. India Head and Neck Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Australia Head and Neck Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Japan Head and Neck Cancer Drugs Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Class
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. South Korea Head and Neck Cancer Drugs Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Class
        • 6.3.5.2.2. By Distribution Channel

7. Europe Head and Neck Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Head and Neck Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Head and Neck Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Spain Head and Neck Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Head and Neck Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. United Kingdom Head and Neck Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. North America Head and Neck Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Head and Neck Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Mexico Head and Neck Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Canada Head and Neck Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel

9. South America Head and Neck Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Head and Neck Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Head and Neck Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Head and Neck Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Head and Neck Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Head and Neck Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Head and Neck Cancer Drugs Market Outlook
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Head and Neck Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Head and Neck Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Merck & Co., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Eli Lilly and Company
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. Astrazeneca Plc.
  • 15.5. Fresenius Medical Care AG & CO. KGAA
  • 15.6. F.Hoffmann-la Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer